Loading...
•
Jun 30, 2024
Sotera Health Q2 2024 Earnings Report
Sotera Health's Q2 2024 performance saw revenue growth, but net income decreased due to debt refinancing charges.
Key Takeaways
Sotera Health reported an 8% increase in net revenues to $277 million for Q2 2024. However, net income decreased to $9 million, or $0.03 per diluted share, primarily due to charges associated with debt refinancing. Adjusted EBITDA increased by 7% to $137 million, while Adjusted EPS declined slightly to $0.19.
Net revenues for Q2 2024 increased by 8% to $277 million compared to Q2 2023.
Net income for Q2 2024 was $9 million, or $0.03 per diluted share, down from $24 million, or $0.08 per diluted share in Q2 2023.
Adjusted EBITDA for Q2 2024 increased by 7% to $137 million compared to Q2 2023.
The company successfully refinanced its debt structure, extending debt maturities to 2031 and reaffirmed its 2024 outlook.
Sotera Health
Sotera Health
Sotera Health Revenue by Segment
Revenue by Segment
Sterigenics Revenue
CapyFin.comNordion Revenue
CapyFin.comNelson Labs Revenue
CapyFin.com Forward Guidance
Sotera Health reaffirmed its 2024 outlook.
Positive Outlook
- Net revenues and Adjusted EBITDA growth in the range of 4.0% to 6.0%.
- Interest Expense in the range of $165 million to $175 million.
- Tax rate applicable to Adjusted Net Income in the range of 31.5% to 34.5%.
- Adjusted EPS in the range of $0.67 to $0.75.
- Capital expenditures in the range of $205 million to $225 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income